130 related articles for article (PubMed ID: 38531977)
1. Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL; Suh D; Markley JC; Smith OM; King C; Goldberg GL; Jenq R; Holland AM; Grubin J; Cabrera-Perez J; Brentjens RJ; Lu SX; Rizzuto G; Sant'Angelo DB; Riviere I; Sadelain M; Heller G; Zúñiga-Pflücker JC; Lu C; van den Brink MRM
Nat Biotechnol; 2024 Apr; 42(4):674. PubMed ID: 38531977
[No Abstract] [Full Text] [Related]
2. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL; Suh D; Markley JC; Smith OM; King C; Goldberg GL; Jenq R; Holland AM; Grubin J; Cabrera-Perez J; Brentjens RJ; Lu SX; Rizzuto G; Sant'Angelo DB; Riviere I; Sadelain M; Heller G; Zúñiga-Pflücker JC; Lu C; van den Brink MR
Nat Biotechnol; 2008 Apr; 26(4):453-61. PubMed ID: 18376399
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
5. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.
Wang X; Cabrera FG; Sharp KL; Spencer DM; Foster AE; Bayle JH
Mol Ther; 2021 Feb; 29(2):718-733. PubMed ID: 33554868
[TBL] [Abstract][Full Text] [Related]
6. Self recognition in allogeneic radiation bone marrow chimeras. A radiation-resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells.
Singer A; Hathcock KS; Hodes RJ
J Exp Med; 1981 May; 153(5):1286-301. PubMed ID: 6166716
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
8. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
Ji YH; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
Bone Marrow Transplant; 2003 Sep; 32(5):495-504. PubMed ID: 12942096
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: Neoantigen-specific stem cell memory-like CD4
Brightman SE; Becker A; Thota RR; Naradikian MS; Chihab L; Zavala KS; Ramamoorthy Premlal AL; Griswold RQ; Dolina JS; Cohen EEW; Miller AM; Peters B; Schoenberger SP
Nat Immunol; 2023 Aug; 24(8):1391. PubMed ID: 37464051
[No Abstract] [Full Text] [Related]
11. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.
Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS
Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537
[TBL] [Abstract][Full Text] [Related]
12. The allogeneic response and tumor immunity.
Fabre JW
Nat Med; 2001 Jun; 7(6):649-52. PubMed ID: 11385492
[TBL] [Abstract][Full Text] [Related]
13. Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours.
Ong CEB; Cheng Y; Siddle HV; Lyons AB; Woods GM; Flies AS
Open Biol; 2022 Oct; 12(10):220208. PubMed ID: 36259237
[TBL] [Abstract][Full Text] [Related]
14. Redirected tumor-specific allogeneic T cells for universal treatment of cancer.
Marcus A; Waks T; Eshhar Z
Blood; 2011 Jul; 118(4):975-83. PubMed ID: 21653325
[TBL] [Abstract][Full Text] [Related]
15. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
[TBL] [Abstract][Full Text] [Related]
16. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.
Ghosh A; Holland AM; van den Brink MR
Immunol Rev; 2014 Jan; 257(1):226-36. PubMed ID: 24329800
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
[TBL] [Abstract][Full Text] [Related]
19. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
[TBL] [Abstract][Full Text] [Related]
20. The structural basis of T-cell allorecognition.
Whitelegg A; Barber LD
Tissue Antigens; 2004 Feb; 63(2):101-8. PubMed ID: 14705981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
